Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive Pulmonary Sarcomatoid Carcinoma.

Intern MedMar 17, 2026 (epub)
Case ReportOncology (Medical)Pulmonology

Takeru Ichikawa, Kenichiro Kudo, Yuki Takigawa et al.

✦ AI-curated · Sources linked

Case in brief

Two men, aged 69 and 66 years, had metastatic pulmonary sarcomatoid carcinoma with KRAS G12C mutations. Both received chemotherapy combined with durvalumab and tremelimumab using the POSEIDON regimen. Their cancers showed a complete response in one case and a partial response in the other, with sustained clinical benefit reported. The authors suggest this regimen may be a therapeutic option for this patient group.

What made this case unusual

Both cases involved metastatic KRAS G12C-positive pulmonary sarcomatoid carcinoma, and each had a sustained response to chemotherapy combined with durvalumab and tremelimumab.

Diagnostic / clinical pearl

In these two cases, metastatic KRAS G12C-positive pulmonary sarcomatoid carcinoma responded to chemotherapy combined with durvalumab and tremelimumab, with one complete and one partial response.

Source

PubMed · PMID 41850829

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.